BOSENTAN ACTAVIS 62.5 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

bosentan actavis 62.5 mg tabletti, kalvopäällysteinen

actavis group ptc ehf - bosentanum monohydricum - tabletti, kalvopäällysteinen - 62.5 mg - bosentaani

BOSENTAN RATIOPHARM 62.5 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

bosentan ratiopharm 62.5 mg tabletti, kalvopäällysteinen

ratiopharm gmbh - bosentanum monohydricum - tabletti, kalvopäällysteinen - 62.5 mg - bosentaani

BOSENTAN RATIOPHARM 125 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

bosentan ratiopharm 125 mg tabletti, kalvopäällysteinen

ratiopharm gmbh - bosentanum monohydricum - tabletti, kalvopäällysteinen - 125 mg - bosentaani

BOSENTAN SANDOZ 62.5 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

bosentan sandoz 62.5 mg tabletti, kalvopäällysteinen

sandoz a/s sandoz a/s - bosentanum monohydricum - tabletti, kalvopäällysteinen - 62.5 mg - bosentaani

BOSENTAN SANDOZ 125 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

bosentan sandoz 125 mg tabletti, kalvopäällysteinen

sandoz a/s sandoz a/s - bosentanum monohydricum - tabletti, kalvopäällysteinen - 125 mg - bosentaani

BOSENTAN CIPLA 62.5 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

bosentan cipla 62.5 mg tabletti, kalvopäällysteinen

cipla europe nv - bosentanum monohydricum - tabletti, kalvopäällysteinen - 62.5 mg - bosentaani

BOSENTAN CIPLA 125 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

bosentan cipla 125 mg tabletti, kalvopäällysteinen

cipla europe nv - bosentanum monohydricum - tabletti, kalvopäällysteinen - 125 mg - bosentaani

BOSENTAN AMNEAL 62.5 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

bosentan amneal 62.5 mg tabletti, kalvopäällysteinen

amneal pharma europe limited - bosentanum monohydricum - tabletti, kalvopäällysteinen - 62.5 mg - bosentaani

BOSENTAN AMNEAL 125 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

bosentan amneal 125 mg tabletti, kalvopäällysteinen

amneal pharma europe limited - bosentanum monohydricum - tabletti, kalvopäällysteinen - 125 mg - bosentaani

Dupixent Euroopan unioni - suomi - EMA (European Medicines Agency)

dupixent

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatiittiautia lukuun ottamatta kortikosteroideja - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.